Redefining the Assembly Line of Medicine: How Precision Chroma is Rewriting the Rules of Biomanufacturing
Discovering and developing a breakthrough biological drug is a monumental scientific achievement. Yet an equally complex challenge that is often overlooked is the sheer difficulty of manufacturing that drug at a commercial scale.
Precision Chroma, a pioneering New Zealand deep tech company, is completely reimagining this process. By swapping out outdated, unpredictable manufacturing methods for advanced 3D printed technology, they are paving the way for life-changing therapies to be produced faster, cheaper, and at a scale never before possible.
Breaking the Engineering Bottleneck
The current standard for manufacturing biological drugs is incredibly intricate and notoriously difficult to control. For decades, the industry has relied on columns tightly packed with tiny, irregular beads to filter and purify biological compounds. Because the fluid has to weave blindly through these random gaps, engineers have zero control over the internal flow paths.
Precision Chroma achieves perfect control by throwing out the random beads and using high-precision 3D printing instead. CEO and founder Sean Feast explains:
"Precision Chroma is simplifying the way biological therapeutics are manufactured. We take a big biological soup and simplify it into a purified product in a single step."
This flawless internal highway collapses multiple messy manufacturing steps into one fast process. As Sean notes, the flow-on effects are industry-defining.
"Ideally this means that patients who need these drugs receive them faster, they are cheaper, and they become more accessible to everyone."
From the Lab Bench to a 1,000x Scale Up
Proving a concept works on a computer screen is one thing, but translating it into a viable commercial business requires immense operational execution. Precision Chroma has already successfully scaled their laboratory process by an incredible 1,000x.
To validate this milestone and prepare for the global stage, they partnered early with Bridgewest Ventures. For Sean, making the leap from a technical engineer to a startup CEO required a partner who offered heavy operational lifting alongside capital. Sean Shares:
"It is a tough transition. You go from a small team where you are driving the R&D and doing the hands-on work in the lab, and at a certain point one day you realise you have not been in the lab for a month. If you have a great idea or a great technology, I would highly recommend Bridgewest Ventures as your first port of call. They provide more than just funding in terms of support, everything from regulatory to accounting to finance to business acumen."
This hands-on, highly active partnership has allowed the Precision Chroma team to derisk their technology while navigating complex corporate strategy without fear of failure.
"The benefit of having that approach from Bridgewest Ventures is I am so much more willing to give them a call to let them know something is not right or we have a challenge," Sean adds. "Knowing that they are going to be solution-oriented is such a confidence to me as a founder to know that mistakes can be made and they can be fixed."
Building for the World from New Zealand
With their technology successfully derisked at a pilot level, Precision Chroma is now focused on building a dedicated pilot manufacturing facility right here in Christchurch. This facility will serve as the final technical validation point, implementing world-class quality management systems to prepare the company for deep integration with the world's largest pharmaceutical companies.
Targeting a massive $15 billion global purification market that is growing by over 10% each year, Precision Chroma is unlocking an entirely new era of drug production.
By replacing chaos with perfect engineering order, Sean and his team are proving that the next generation of global medical manufacturing is being built right here in New Zealand.